Why Is It Important to Look at Cross-Reactivity Among Beta-Lactams?
JUL 12, 2017 | CONTAGION® EDITORIAL STAFF
Meghan Jeffres, PharmD, assistant professor in the Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy, explains the importance of discussing cross-reactivity among beta-lactams.
Interview Transcript (slightly modified for readability)
“The reason we are discussing cross-reactivity among beta-lactams and why this has become such a ‘hot-button’ issue is that the number of people labeled as penicillin-allergic in the United States is anywhere between 10% and 15%. We think that with this particular group—because they are labeled as penicillin-allergic—physicians and the prescribers avoid using beta-lactams.
When you avoid using beta-lactams, you increase the use of vancomycin and flouroquinolones. The use of those secondary antibiotics increases cost, increases super infections, and decreases clinical outcomes. They are inferior to beta-lactams.
Therefore, we want to decrease the fear of using beta-lactams in patients that are labeled as penicillin-allergic, [and this is why] we are spending a lot of time talking about cross-reactivity in general versus cross-reactivity specifically.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
We break down our top HIV news stories of 2017. Did you read them all?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512